<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">J Subst Use Addict Treat</journal-id><journal-id journal-id-type="iso-abbrev">J Subst Use Addict Treat</journal-id><journal-id journal-id-type="pmc-domain-id">319</journal-id><journal-id journal-id-type="pmc-domain">nihpa</journal-id><journal-title-group><journal-title>Journal of substance use and addiction treatment</journal-title></journal-title-group><issn pub-type="ppub">2949-8767</issn><issn pub-type="epub">2949-8759</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>NIHPA Author Manuscripts</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11060916</article-id><article-id pub-id-type="pmcid-ver">PMC11060916.319</article-id><article-id pub-id-type="pmcaid">11060916</article-id><article-id pub-id-type="pmcaiid">11060916</article-id><article-id pub-id-type="manuscript-id">NIHMS1962496</article-id><article-id pub-id-type="pmid">38262559</article-id><article-id pub-id-type="doi">10.1016/j.josat.2024.209298</article-id><article-id pub-id-type="manuscript-id-alternative">NIHMS1962496</article-id><article-id pub-id-type="manuscript-id-alternative">NIHPA1962496</article-id><article-version article-version-type="pmc-version">319</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Medications for Opioid Use Disorder Associated with Reduced Readmissions for Patients with Severe Injection-Related Infections: A Matched Cohort Study</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-2139-8321</contrib-id><name name-style="western"><surname>Robertson</surname><given-names initials="NM">Nicole M</given-names></name><degrees>MD, MPH</degrees><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-2699-9989</contrib-id><name name-style="western"><surname>Mangino</surname><given-names initials="AA">Anthony A.</given-names></name><degrees>PhD</degrees><xref rid="A2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>South</surname><given-names initials="AM">Anna-Maria</given-names></name><degrees>MD</degrees><xref rid="A3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Fanucchi</surname><given-names initials="LC">Laura C.</given-names></name><degrees>MD, MPH</degrees><xref rid="A4" ref-type="aff">4</xref></contrib></contrib-group><aff id="A1"><label>1</label>Department of Internal Medicine, Johns Hopkins School of Medicine, Baltimore, MD</aff><aff id="A2"><label>2</label>Department of Biostatistics, University of Kentucky, Lexington, KY, USA</aff><aff id="A3"><label>3</label>Division of Hospital Medicine, Department of Internal Medicine, University of Kentucky College of Medicine, Lexington, KY, USA</aff><aff id="A4"><label>4</label>Division of Infectious Diseases, Center on Drug and Alcohol Research, Department of Internal Medicine, University of Kentucky College of Medicine, Lexington, KY, USA</aff><author-notes><corresp id="CR1"><bold>Corresponding Author:</bold> Laura Fanucchi MD, MPH, UK Center on Drug and Alcohol Research 845 Angliana Ave. Lexington, KY 40508, <email>laura.fanucchi@uky.edu</email></corresp></author-notes><pub-date pub-type="ppub"><month>5</month><year>2024</year></pub-date><pub-date pub-type="epub"><day>21</day><month>1</month><year>2024</year></pub-date><volume>160</volume><issue-id pub-id-type="pmc-issue-id">461409</issue-id><fpage>209298</fpage><lpage>209298</lpage><pub-history><event event-type="nihms-submitted"><date><day>29</day><month>01</month><year>2024</year></date></event><event event-type="pmc-release"><date><day>01</day><month>05</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>01</day><month>05</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-05-01 00:25:14.317"><day>01</day><month>05</month><year>2025</year></date></event></pub-history><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="nihms-1962496.pdf"/><abstract id="ABS1"><sec id="S1"><title>Introduction</title><p id="P1">Hospitalizations due to severe injection-related infections (SIRIs) and patient-directed discharge (PDD) in people who inject drugs (PWID) are increasing, but research on readmission outcomes at PDD is limited. In this retrospective, matched cohort study we evaluated predictors of 30-day readmission by discharge status among PWID.</p></sec><sec id="S2"><title>Methods</title><p id="P2">Among patients diagnosed with SIRIs at a tertiary hospital, Fisher&#8217;s exact tests assessed differences in readmission rates by discharge status. Medications for opioid use disorder (MOUD) at discharge was defined as either having a buprenorphine dose dispensed within 24 hours of discharge and buprenorphine being included in the discharge summary as a prescription, or a methadone dose dispensed inpatient within 24 hours of discharge. Logistic regression analyses evaluated predictors of readmission outcomes.</p></sec><sec id="S3"><title>Results</title><p id="P3">Among 148 PWID with SIRI diagnosis, 30-day readmission rate following PDD was higher than standard discharge (25.7% vs. 9.5%, p=0.016) and MOUD decreased odds of 30-day readmission (OR=0.32, 95% CI: 0.12,0.83, p=0.012). More than 7 missed days of antibiotic treatment increased odds of 30-day readmission (OR 4.65, 95% CI: 1.14, 31.72, p=0.030) within PDD patients.</p></sec><sec id="S4"><title>Conclusions</title><p id="P4">PDD carries higher 30-day readmission rate compared to standard discharge. Strategies to reduce PDD rates and increase MOUD initiation may improve readmission outcomes.</p></sec></abstract><kwd-group><kwd>patient directed discharge</kwd><kwd>opioid use disorder</kwd><kwd>severe injection-related infection</kwd><kwd>readmission</kwd><kwd>injection drug use</kwd><kwd>addiction</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>